The last 12 months continue to show advances in the treatment of non-small cell lung cancer (NSCLC), once again most notably in the sector of precision treatment. Importantly advances in the treatment of small cell lung cancer using newer precision medicines and immunotherapy also appear promising. Recent studies show that many individuals that might benefit from these treatments are not receiving them.
Precision medicine continues to impact the lives of lung cancer patients with research into genomics and genetics leading to unprecedented progress in improving outcomes. Tailored treatments have emerged to match a person’s genetic make¬up or a tumor’s genetic profile. As a result, patients with lung cancer now typically re¬ceive molecular testing that guides their physicians in determining which therapies are more likely to boost the chances of survival while limiting the potential for adverse effects. Results from studies evaluating ALK-inhibitors continue to show efficacy and initial studies exploring immunomodulatory approaches using anti-PD-1 and anti-PD-L1 antibodies have demonstrated promising results in lung cancer. The cancer research community is moving forward in its efforts find more effective treatment for patients with lung cancer. Current clinical trials are taking innovative approaches to how therapies for both advanced and early-stage lung cancers are studied.
CancerConnect News coverage of advances in the management of lung cancer included the following key developments:
Non-Small Cell Lung Cancer
- Many Late Stage Lung Cancer Patients do not Receive Treatment
- Keytruda® Demonstrates Superior Survival Compared to Chemotherapy as First-Line Treatment for Advanced Non-Small Cell Lung Cancer
- Tagrisso®: New Standard of Care for Certain Lung Cancer
- Precision Medicine Guides NSCLC Cancer Treatment: All Patients Should Undergo Molecular Testing
- Tecentriq® Improves NSCLC Survival Compared to Chemotherapy Regardless of PD-L1 Status
- Whole-Brain Radiotherapy Fails to Benefit Most Patients with Lung Cancer
- FDA Grants Breakthrough Therapy Designation for MPDL3280A, an anti-PDL1 Investigational Cancer Immunotherapy for Non-Small Cell Lung Cancer
Small Cell Lung Cancer
- First Targeted Therapy Shows Promise in Small Cell Lung Cancer
- Two-Drug Immunotherapy Deemed Safe for Small Cell Lung Cancer Patients, Moffitt Study Shows
LEARNING MORE ABOUT LUNG CANCER
Knowledge is power. Are you facing a new diagnosis, recurrence, living with metastatic disease, or supporting a loved one through their cancer journey?
- Sign up for monthly newsletters on lung cancer here.
- Get the facts about lung cancer here.
- Join ongoing discussions with other individuals affected by lung cancer in the CancerConnect private online support group here.
- Follow CancerConnect on Facebook and Twitter.
Copyright © 2018 CancerConnect. All Rights Reserved.